Is ASX stock 4DMedical defying tech tumble?
4DMedical is charging ahead after FDA clearance for its game-changing CTVQ technology and a massive $150M institutional placement. This fresh capital infusion, alongside U.S. reimbursement and top-tier hospital adoptions, signals strong momentum for shareholders in respiratory imaging.
4DMedical Limited (ASX:4DX)
is a respiratory imaging technology company who has recently announced an institutional placement and strong Q1 FY26 results. These developments position it for accelerated U.S. commercialization of its FDA cleared CTVQ product.
The company has announced on 15 January that it has secured commitments for a $150M placement at $3.80 per share (11.4% discount) which was cornerstoned by new global institutions with strong existing shareholder support. Dilution was limited to 3.86% via repurposing of 18.7M shares. Proceeds from this placement will target U.S. sales/marketing for CTVQ, customer support, R&D and working capital and will boost pro forma cash over $200M.
Q1 FY26 (ended Sep 30, 2025) has delivered FDA clearance for CTVQ with immediate CMS reimbursement at US$650.50/scan atop routine CT fees. Stanford along with University of Miami, Cleveland clinic and UC San Diego have adopted CTVQ commercially.
Operating revenue has reached $1.4M (90%+ gross margins) with SaaS at 409 global sites (+50.9% YoY) generating 74,345 scans (+105.6% YoY). Cash balance has reached $33.5M (up from prior) which was aided by $10M Pro Medicus investment, $6M R&D tax receipt and $20.5M options exercises. Net operating cash outflows improved to $3.3M, with 10+ quarters' runway.
4DMedical is looking forward at rapid CTVQ rollout at KOL sites and to leverage $2.6B+ global market to displace nuclear VQ scans, with Philips partnerships and RSNA 2025 showcase ahead. Strong balance sheet funds profitability push in lung health tech creating substantial shareholder value.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
